NCT01536743View on ClinicalTrials.gov

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 15, 2011

Primary Completion Date

February 24, 2020

Study Completion Date

February 24, 2020

Conditions
Ovarian Epithelial Carcinoma
Interventions
DRUG

PD0332991

"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."

Trial Locations (1)

90095

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT01536743 - A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression | Biotech Hunter | Biotech Hunter